Sadanori Furudate

Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 101 citations

Medicine, Immunology, Oncology +16

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 90 citations · Full text

Medicine, Dermatology, Oncology +17

<scp>HLA</scp>‐<scp>DRB</scp>1*04:05 in two cases of Vogt–Koyanagi–Harada disease‐like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy

Taku Fujimura, Yumi Kambayashi, Kayo Tanita et al. · The Journal of Dermatology · 2018 · 80 citations

Medicine, Oncology, Ophthalmology +14

The possible interaction between periostin expressed by cancer stroma and tumor‐associated macrophages in developing mycosis fungoides

Sadanori Furudate, Taku Fujimura, Aya Kakizaki et al. · Experimental Dermatology · 2015 · 79 citations

Medicine, Immunology, Pathology +17

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages

Aya Kakizaki, Taku Fujimura, Sadanori Furudate et al. · OncoImmunology · 2015 · 74 citations · Full text

Medicine, Immunology, Oncology +17